Insmed (INSM) Capital Expenditures Growth (3y) (2014 - 2026)
Insmed (INSM) Capital Expenditures Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.04 Bn | 467.25 Bn | 1.35 Bn | -12.25% |
| 5 | Vertex Pharmaceuticals | 122.28 Bn | 115.03 Bn | 2.59 Bn | 46.88% |
| 6 | Regeneron Pharmaceuticals | 70.07 Bn | 61.31 Bn | 3.31 Bn | 8.97% |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | - |
| 8 | Argenx Se | 56.16 Bn | 50.98 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.56 Bn | 34.55 Bn | 959.66 Mn | 16.27% |
| 10 | Insmed | 22.92 Bn | 21.70 Bn | 258.54 Mn | 0.80% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.80% |
| Dec 31, 2025 | 79.13% |
| Sep 30, 2025 | -68.19% |
| Jun 30, 2025 | 6.26% |
| Mar 31, 2025 | 80.90% |
| Dec 31, 2024 | -29.03% |
| Sep 30, 2024 | 89.47% |
| Jun 30, 2024 | -0.66% |
| Mar 31, 2024 | -26.35% |
| Dec 31, 2023 | 13.98% |
| Sep 30, 2023 | 33.80% |
| Jun 30, 2023 | 34.12% |
| Mar 31, 2023 | 29.41% |
| Dec 31, 2022 | -28.40% |
| Sep 30, 2022 | 37.79% |
| Jun 30, 2022 | -16.80% |
| Mar 31, 2022 | -37.73% |
| Dec 31, 2021 | 11.79% |
| Jun 30, 2021 | -41.08% |
| Mar 31, 2021 | 54.36% |